Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) [Phase 1]

View source ↗

Summary

Phase 1 safety and preliminary efficacy study of pembrolizumab in Chinese patients with locally advanced or metastatic melanoma; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2019-03-21